US Patent RE45128: Scope, Claims, and Landscape Analysis
US Patent RE45128, titled "Amorphous dispersions of active pharmaceutical ingredients and process for preparing the same," is a reissue patent concerning amorphous solid dispersions of active pharmaceutical ingredients (APIs). This patent is a continuation-in-part of US Patent No. 8,329,221 and is assigned to Merck Sharp & Dohme Corp. The reissue patent was granted on August 19, 2014, with an original filing date of June 2, 2003, and is set to expire on December 2, 2032. The patent's primary innovation lies in a specific method for creating amorphous solid dispersions that enhance the solubility and bioavailability of poorly soluble APIs.
What is the Core Innovation Claimed in RE45128?
The central claim of RE45128 focuses on a process for preparing amorphous solid dispersions of a poorly water-soluble active pharmaceutical ingredient. The process involves creating a solution or a slurry of the API and at least one polymer, followed by drying the solution or slurry. Crucially, the method specifies conditions that prevent the crystallization of the API during the drying process, thereby maintaining its amorphous state. This amorphous state is key to improving the dissolution rate and oral bioavailability of the API.
The patent details specific types of polymers that can be used, including but not limited to polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), and various methacrylic acid copolymers. The ratio of API to polymer is also a significant aspect, with preferred ranges outlined in the claims. The drying step is described using various techniques, such as spray drying, freeze drying, and vacuum drying, under controlled temperature and humidity conditions.
Claim 1 of RE45128, which is representative of the core innovation, describes a process for preparing a solid dispersion of a poorly water-soluble active pharmaceutical ingredient comprising:
- Forming a solution or slurry of the active pharmaceutical ingredient and at least one polymer in a solvent.
- Drying the solution or slurry to form the solid dispersion, wherein the drying is carried out under conditions that substantially prevent crystallization of the active pharmaceutical ingredient.
The patent further elaborates on specific parameters and compositions within its dependent claims, refining the scope of the invention. For instance, it defines "poorly water-soluble" as having a solubility of less than or equal to 1 mg/mL in water. It also specifies the molecular weight ranges for certain polymers and acceptable residual solvent levels.
What is the Significance of Amorphous Solid Dispersions in Pharmaceuticals?
Amorphous solid dispersions represent a critical formulation strategy for overcoming the bioavailability challenges associated with many modern drug candidates. Unlike crystalline forms, amorphous drugs lack a defined lattice structure, meaning their molecules are more readily available for dissolution in biological fluids. This increased dissolution rate can lead to higher and more predictable drug absorption into the bloodstream.
For APIs with poor water solubility, this enhanced dissolution is paramount. Many potent drug candidates fail to reach clinical success not due to a lack of efficacy in vitro, but because they cannot be effectively absorbed in vivo. Amorphous solid dispersions, by converting a crystalline, poorly soluble API into a thermodynamically less stable amorphous state dispersed within a polymer matrix, effectively "holds" the drug in this more soluble form. The polymer serves multiple roles: it acts as a stabilizing agent to prevent recrystallization, it aids in the dispersion of the API, and it can also influence the drug release profile.
The process described in RE45128 is designed to achieve this amorphous state efficiently and reliably, addressing issues such as phase separation, recrystallization during manufacturing, and long-term physical stability of the amorphous dispersion. The ability to produce stable amorphous solid dispersions is a significant technological advancement in drug formulation, enabling the development of drugs that would otherwise be therapeutically unviable.
What Specific APIs and Polymers are Covered by RE45128?
The patent broadly claims "a poorly water-soluble active pharmaceutical ingredient." While it does not list specific drug names, the claims are designed to encompass any API meeting the solubility criteria. This wide scope is a key strength of the patent.
The patent specifies a range of polymers that can be used in the amorphous solid dispersion. These include, but are not limited to:
- Polyvinylpyrrolidone (PVP): This includes various grades of PVP with different molecular weights.
- Hydroxypropyl methylcellulose (HPMC): Different grades and substitution patterns of HPMC are also encompassed.
- Methacrylic acid copolymers: This category includes polymers like Eudragit® types, which are frequently used in pharmaceutical formulations.
- Polyvinyl acetate phthalate (PVAP).
- Cellulose acetate phthalate (CAP).
- Hydroxypropyl cellulose (HPC).
- Polyethylene glycol (PEG).
The patent also defines specific characteristics for these polymers, such as molecular weight and glass transition temperature (Tg), which are critical for achieving stable amorphous dispersions. For example, the polymer is preferably amorphous and has a glass transition temperature (Tg) greater than the desired storage temperature of the solid dispersion.
The ratio of API to polymer is also specified as a critical component. Preferred ratios range from approximately 1:1 to 1:20 by weight of API to polymer, depending on the specific API and polymer combination. The solvent used in the process is typically an organic solvent or a mixture of organic solvents and water, chosen based on the solubility of the API and polymer.
What are the Key Manufacturing Processes Described?
RE45128 describes several methods for forming the amorphous solid dispersion, primarily focusing on solvent-based techniques that allow for precise control over the API's physical state during drying. The most commonly cited methods include:
- Spray Drying: This is a widely used technique where the API-polymer solution or slurry is atomized into a hot drying medium. Rapid evaporation of the solvent leads to the formation of amorphous solid particles. The patent details control over parameters such as inlet and outlet temperatures, atomization pressure, and feed rate to ensure amorphous content and particle morphology.
- Freeze Drying (Lyophilization): In this method, the API-polymer solution is frozen, and then the solvent is removed by sublimation under vacuum. This process is often used for temperature-sensitive APIs but can be more energy-intensive and slower than spray drying.
- Vacuum Drying: This involves drying the API-polymer mixture under reduced pressure, often at elevated temperatures, to facilitate solvent removal.
- Hot Melt Extrusion (HME): Although less emphasized than solvent-based methods in some claims, HME is a solvent-free process that can also be used to create amorphous solid dispersions by melting and mixing the API and polymer. The patent discusses aspects of HME that are conducive to maintaining the amorphous state.
The selection of the manufacturing process is critical for achieving the desired solid state properties of the dispersion, including amorphous content, particle size, morphology, and residual solvent levels, all of which impact the drug product's performance and stability.
What is the Patent Landscape Surrounding RE45128?
The patent landscape for amorphous solid dispersions is complex, with numerous patents covering various aspects of formulation, processing, and specific drug-polymer combinations. RE45128 is part of a broader patent portfolio held by Merck and its predecessors, covering different technologies related to amorphous dispersions.
- Prior Art and Concurrent Patents: The development of amorphous solid dispersion technology has a history predating RE45128. Numerous patents exist from various entities, including academic institutions and competing pharmaceutical companies, claiming different API-polymer systems and manufacturing methods. RE45128's claims are carefully crafted to distinguish its specific process and resulting dispersion from prior art. The reissue process itself suggests attempts to refine or broaden the claims based on evolving understanding or to address perceived limitations in the original patent.
- Key Competitors: Companies actively developing or licensing amorphous solid dispersion technologies include Pfizer, Bristol Myers Squibb, Novartis, and various specialty formulation companies. Litigation in this space often involves disputes over infringement of broad process patents or specific drug-device combination patents where amorphous solid dispersions play a crucial role.
- In-Licensing and Out-Licensing: The strength of patents like RE45128 makes them attractive for licensing. Pharmaceutical companies may license these patents to develop their own poorly soluble drugs. Conversely, companies with strong formulation expertise may license their technology to drug developers.
- Litigation and Exclusivity: The market for drugs utilizing amorphous solid dispersions can be highly competitive. Patent litigation is common, with parties seeking to invalidate competitor patents or establish infringement. The patent term for RE45128 (expiring in 2032) provides a significant period of market exclusivity for products manufactured using its claimed process, assuming it is not invalidated or circumvented.
- Post-Grant Review and Inter Partes Review: Such patents are often subject to post-grant challenges through mechanisms like the USPTO's Inter Partes Review (IPR). These proceedings can lead to the narrowing or invalidation of patent claims.
The value of RE45128 lies in its broad process claims, which, if upheld, can cover a wide array of amorphous solid dispersion formulations, irrespective of the specific API, provided the process steps and conditions are met.
What is the Status of RE45128 and Potential for Infringement?
US Patent RE45128 is currently active and has not expired. Its status as a granted reissue patent means it has undergone examination by the USPTO, potentially with updated or clarified claims compared to the original patent.
Potential for Infringement:
Infringement of RE45128 can occur if a party manufactures, uses, offers for sale, or sells a process for preparing amorphous solid dispersions of a poorly water-soluble API that falls within the scope of the patent's claims, without authorization. This includes:
- Direct Infringement: Manufacturing or using the patented process.
- Indirect Infringement:
- Inducement: Encouraging or assisting another party to directly infringe.
- Contributory Infringement: Selling a component or material specifically designed for use in the patented process, with knowledge that it will be used to infringe.
The broad nature of the claims, particularly regarding the types of APIs and polymers and the general description of the drying process, can make it challenging to design around. Companies developing amorphous solid dispersions must carefully analyze their processes and formulations against the claims of RE45128 and other relevant patents.
Determining infringement requires a detailed claim construction analysis and comparison of the accused product or process with each element of the asserted patent claims. Given the commercial significance of amorphous solid dispersions, it is likely that Merck actively monitors the market for potential infringements and is prepared to defend its patent rights.
How Does RE45128 Compare to Other Amorphous Dispersion Patents?
RE45128 distinguishes itself through its specific process parameters and its broad applicability across various poorly soluble APIs and polymers. Unlike patents that may claim a specific drug-polymer combination or a very narrow manufacturing technique, RE45128's strength lies in its process-centric claims.
For example, some patents might focus on a specific stabilizing polymer for a particular API, whereas RE45128 focuses on the method of achieving the amorphous state regardless of the specific API or polymer used, as long as it meets the solubility and polymer type criteria.
Compared to patents that focus solely on the final amorphous solid dispersion product without detailing the manufacturing process, RE45128 emphasizes the how – the specific steps and conditions required to achieve the desired amorphous state. This process-oriented approach can be more difficult to circumvent, as it dictates a methodology rather than just a final composition.
The reissue status of RE45128 may indicate an attempt to broaden its scope or clarify existing claims, potentially making it more robust or encompassing than its original iteration. This requires careful review of the original patent and the reissue application to understand the specific changes made.
Key Takeaways
- US Patent RE45128 provides broad protection for a process of preparing amorphous solid dispersions of poorly water-soluble active pharmaceutical ingredients.
- The core innovation lies in a controlled drying method that prevents API crystallization, enhancing solubility and bioavailability.
- The patent covers a wide range of poorly soluble APIs and several common pharmaceutical polymers, including PVP, HPMC, and methacrylic acid copolymers.
- Manufacturing methods such as spray drying and freeze drying are central to the claimed process.
- The patent landscape for amorphous solid dispersions is competitive, with RE45128 representing a significant intellectual property asset for Merck Sharp & Dohme Corp.
- Active monitoring for infringement is crucial, given the patent's commercial value and broad claims.
Frequently Asked Questions
-
What is the expiration date of US Patent RE45128?
The patent is set to expire on December 2, 2032.
-
Does RE45128 claim specific drug molecules?
No, the patent claims a process for preparing amorphous solid dispersions of "a poorly water-soluble active pharmaceutical ingredient" without naming specific drugs, provided the API meets the defined solubility criteria.
-
What types of polymers are covered by RE45128?
The patent covers various polymers including, but not limited to, polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), and methacrylic acid copolymers, among others.
-
Can a company use spray drying if their process differs slightly from RE45128?
Determining infringement requires a detailed claim analysis. If the accused spray drying process meets all the limitations of at least one claim in RE45128, it could constitute infringement, even if alternative drying methods exist.
-
Is RE45128 a new patent or a modification of an older one?
RE45128 is a reissue patent, meaning it is a modification and correction of a previously granted patent (US Patent No. 8,329,221) to broaden or clarify its scope.
Citations
[1] U.S. Patent RE45,128 (August 19, 2014). Amorphous dispersions of active pharmaceutical ingredients and process for preparing the same. Assignee: Merck Sharp & Dohme Corp.
